Development of Disease-Specific Drug Delivery Vehicles
Development of Disease-Specific Drug Delivery Vehicles
批准号:
7477077
负责人:
OMID C FAROKHZAD
金额:
$19.29万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-03-01 至 2010-06-30
关键词:
AchievementAffinityAmino Acid SequenceAntibodiesAntigen TargetingAntigensAntineoplastic AgentsBindingCell LineCell surfaceCharacteristicsClassificationConditionDNADetectionDevelopmentDiagnosisDiagnosticDiseaseDoseDrug Delivery SystemsEffectivenessEncapsulatedEndocytosisEthylene GlycolsEvaluationEvolutionFutureGoalsImageImmunohistochemistryIn VitroLigandsMalignant NeoplasmsMalignant neoplasm of prostateMediatingMethodologyMethodsModalityModelingMolecular TargetNormal tissue morphologyNucleic AcidsPC3 cell linePathologicPatternPharmaceutical PreparationsPolymersProstateProteinsResearchResearch ProposalsScreening procedureSpecificitySurface AntigensSurface of the ProstateSystemTechniquesTechnologyTestingTissuesTumor Antigensantigen bindingaptamercancer cellcancer diagnosiscontrolled releasecopolymercytotoxicethylene glycolextracellularhuman diseasein vivokillingsmouse modelnanoparticlenovelnovel therapeuticsoutcome forecastpoly(lactic acid)prognosticprotein purificationresearch studysizetherapeutic targettooltumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by candidate):
The central aim of this K08 proposal is to develop a technology for disease-specific targeting of controlled release polymer systems using nucleic acid ligands (aptamers) as escort molecules. The targeting of controlled-release polymer systems is desirable especially when treating a condition such as cancer where it is important that a cytotoxic dose of the drug is delivered to cancer cells without killing the surrounding noncancerous tissue. To examine and demonstrate the feasibility of our approach, we propose to isolate Prostate Cancer (PCa)-specific aptamers for targeting of drug encapsulated nanoparticle-aptamer controlled release polymer delivery vehicles to PCa. Our research has 4 specific aims: 1) isolation of PCa-specific aptamers; 2) characterization of the target antigen that binds to each aptamer; 3) development of PCa drug delivery vehicles comprised of PCa-specific aptamers conjugated to controlled release polymer nanoparticles; and 4) evaluation of the resulting PCa-specific delivery vehicles in-vitro and in-vivo. We will use a novel screening method to isolate aptamers that bind to antigens expressed on PCa cells. The successful development of our methodology could result in isolating other disease-specific aptamers for virtually any disease as long as there is a differential expression of antigens between the diseased tissue and its normal tissue counterpart. Second, aptamers isolated as part of our strategy would be used as tools to purify their targets using ligand mediated protein purification which could result in the identification of novel disease-specific markers. Third, within the scope of this proposal, disease-specific aptamers would serve as escort molecules for delivering drugs to their respective diseased tissue. However, the utility of disease specific aptamers can extend far beyond our proposed application. For example, disease-specific aptamers will be valuable for generating future diagnostic and prognostic modalities. A conjugate of a disease-specific aptamers with an imaging contrast may be used for detection of a disease focus. Disease-specific aptamers could also be used for histological evaluation of pathologic tissue in a similar manner as antibodies for determining disease diagnosis and prognosis. Therefore, isolating disease-specific aptamers for use in targeted therapeutic and diagnostic applications has broad significance and may impact a myriad of important human diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of Biologics
-
批准号:9017558
-
项目类别:
-
资助金额:$76.93万
-
财政年份:2016
-
负责人:OMID C FAROKHZAD
-
依托单位:
Enhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of Biologics
-
批准号:9199092
-
项目类别:
-
资助金额:$74.66万
-
财政年份:2016
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of Insulin
-
批准号:8459384
-
项目类别:
-
资助金额:$68.29万
-
财政年份:2012
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of Insulin
-
批准号:8830859
-
项目类别:
-
资助金额:$67.23万
-
财政年份:2012
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of FcRn-Targeted Nanoparticles for Efficient Oral Delivery of Insulin
-
批准号:8276050
-
项目类别:
-
资助金额:$76.48万
-
财政年份:2012
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of Disease-Specific Drug Delivery Vehicles
-
批准号:6867511
-
项目类别:
-
资助金额:$19.26万
-
财政年份:2005
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of Disease-Specific Drug Delivery Vehicles
-
批准号:7020645
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2005
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of Disease-Specific Drug Delivery Vehicles
-
批准号:7248611
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2005
-
负责人:OMID C FAROKHZAD
-
依托单位:
Development of Disease-Specific Drug Delivery Vehicles
-
批准号:7650196
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2005
-
负责人:OMID C FAROKHZAD
-
依托单位:
海外基金